Justin Kim
Stock Analyst at Oppenheimer
(1.27)
# 3,680
Out of 5,129 analysts
38
Total ratings
40%
Success rate
-3.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Outperform | $44 → $50 | $27.31 | +83.08% | 5 | Dec 4, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $17 → $16 | $6.26 | +155.59% | 2 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $22.29 | +79.45% | 6 | Nov 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $66.80 | +58.68% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $32.97 | +163.92% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $42.96 | -39.48% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $5.34 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $14.51 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $6.84 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $84.35 | -30.05% | 1 | Jul 18, 2022 |
Pharvaris
Dec 4, 2025
Maintains: Outperform
Price Target: $44 → $50
Current: $27.31
Upside: +83.08%
Zura Bio
Aug 15, 2025
Maintains: Outperform
Price Target: $17 → $16
Current: $6.26
Upside: +155.59%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $22.29
Upside: +79.45%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $66.80
Upside: +58.68%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $32.97
Upside: +163.92%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $42.96
Upside: -39.48%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.34
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $14.51
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.84
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $84.35
Upside: -30.05%